These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Plasma concentrations of estramustine phosphate and its major metabolites in patients with prostatic carcinoma treated with different doses of estramustine phosphate (Estracyt). Gunnarsson PO, Forshell GP, Fritjofsson A, Norlén BJ. Scand J Urol Nephrol; 1981 Mar; 15(3):201-5. PubMed ID: 7323739 [Abstract] [Full Text] [Related]
31. Primary treatment of prostatic carcinoma with estramustine phosphate: preliminary report. Nilsson T, Jonsson G. J Urol; 1976 Feb; 115(2):168-9. PubMed ID: 1249870 [Abstract] [Full Text] [Related]
32. Hormone changes in patients with prostatic carcinoma during treatment with estramustine phosphate. Fosså SD, Fosså J, Aakvaag A. J Urol; 1977 Dec; 118(6):1013-8. PubMed ID: 926240 [Abstract] [Full Text] [Related]
33. The effect of estramustine phosphate on prostatic cancer estimated by transrectal ultrasonotomography. Watanabe H, Ohe H, Ando K, Sawamura Y, Niijima T, Nakamura S, Orikasa S, Tanahashi Y, Imamura K, Yoshida H. Prostate; 1981 Dec; 2(2):155-61. PubMed ID: 7301654 [Abstract] [Full Text] [Related]